Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21591916 | 0.98 | CASP6 (0.61) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL3063225 | 0.92 | CASP6 (0.58) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL8404544 | 0.84 | ALDH1A1 (0.61) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL9374695 | 0.84 | CASP6 (0.71) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL31186675 | 0.84 | ALDH1A1 (0.61) | CASP6ALDH1A1CASP1MAPTHTT | |
| Hydrochloric Acid SCHEMBL30075676 | 0.82 | CASP6 (0.69) | CASP6ALDH1A1CASP1MAPTHTT | |
| Hydrochloric Acid SCHEMBL28888961 | 0.82 | CASP6 (0.69) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL30456422 | 0.81 | ALDH1A1 (0.53) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL3587363 | 0.81 | ALDH1A1 (0.53) | CASP6ALDH1A1CASP1MAPTHTT | |
| SCHEMBL20278401 | 0.77 | ALDH1A1 (0.53) | CASP6ALDH1A1CASP1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| US-12552793-B2 | Purine derivative and medical use thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025049253-A1 | BRIDGED CYCLE‑BASED INHIBITORS OF DNA‑DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| EP-3807278-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552793-B2 | Purine derivative and medical use thereof | PNP, CYP2D6, ADORA1 | CASP6 552/4885ALDH1A1 755/4885CASP1 964/4885 |
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | DTYMK, DCK, PHKG1 | CASP6 1762/4885ALDH1A1 2749/4885CASP1 1760/4885 |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | CASP6 2624/4885ALDH1A1 120/4885CASP1 2643/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | CASP6 2583/4885ALDH1A1 185/4885CASP1 2755/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | CASP6 2963/4885ALDH1A1 2211/4885CASP1 3608/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | CASP6 2537/4885ALDH1A1 1399/4885CASP1 896/4885 |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | CASP6 2217/4885ALDH1A1 1115/4885CASP1 774/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | CASP6 2624/4885ALDH1A1 120/4885CASP1 2643/4885 |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | POLQ, POLK, POLG | CASP6 3706/4885ALDH1A1 4034/4885CASP1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.